Prediction of Delayed Cognitive Impairment in Cardiac Arrest Survivors With Good Neurological Out… (NCT05830422) | Clinical Trial Compass
By InvitationNot Applicable
Prediction of Delayed Cognitive Impairment in Cardiac Arrest Survivors With Good Neurological Outcomes
South Korea40 participantsStarted 2023-11-01
Plain-language summary
The objective of this observational study is to provide basic data for predicting and analyzing the occurrence and causes of delayed cognitive impairment, an important factor in the quality of life, among discharged patients who have received targeted temperature management therapy and experienced favorable neurological outcomes after out-of-hospital cardiac arrest.
The main questions it aims to answer are:
* Can we identify abnormal areas in the brains of patients with delayed cognitive impairment using Brain MRI or positron emission tomography (PET) imaging?
* Is it possible to predict delayed cognitive impairment using biomarkers?
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients who visited the hospital emergency room due to cardiac arrest within 60 months after Institutional Review Board (IRB) approval
* Patients with Glasgow Coma Scale (GCS) less than 8 points after spontaneous circulation recovery
* Patients who are 18 years old or older
* Patients who underwent targeted temperature management (TTM)
* Patients who showed good neurological outcomes with CPC 1-2 points after evaluating the prognosis on days 10-14 after ROSC
Exclusion Criteria:
* Under 18 years of age
* cardiac arrest cause is trauma
* Patients who have not undergone targeted temperature management
* Patients treated with extracorporeal membrane oxygenation (ECMO)
* Patients who were not able to undergo SNSB testing
* Patients who could not be followed up until 6 months after ROSC
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in cognitive impairment
Timeframe: at 10-14 days, 3 months, and 6 months after return of spontaneous circulation